Flunarizine Compared With Propranolol for Migraine in Children
Compares flunarizine and propranolol for reducing migraines in children.
Plain-language title generated from the registry record
Registry title: Comparative Efficacy of Flunarizine and Propanolol in Pediatric Migraine
Key facts
- Where
- Lahore, PakistanSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 8 and 15 years old?
Source: NCT07354126, who can take part
Where in Pakistan
- The Children's Hospital LahoreLahore, PakistanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Muhammad Aamir Latif
- Trial code
- NCT07354126
- Record updated
- 21 January 2026
- Original description
Flunarizine and propranolol have demonstrated efficacy in reducing migraine frequency across age groups, though evidence in pediatric populations remains limited and inconsistent. Therefore, the current study has been planned to evaluate and compare the effectiveness of flunarizine and propranolol in reducing migraine frequency in children aged 8-15 using the Pediatric Migraine Disability Assessment Scale (PedMIDAS) score.Read full original descriptionShow less
Comparative Efficacy of Flunarizine and Propanolol in Pediatric Migraine Using the PedMIDAS Measuring Tool.
Flunarizine and propranolol have demonstrated efficacy in reducing migraine frequency across age groups, though evidence in pediatric populations remains limited and inconsistent. Therefore, the current study has been planned to evaluate and compare the effectiveness of flunarizine and propranolol in reducing migraine frequency in children aged 8-15 using the Pediatric Migraine Disability Assessment Scale (PedMIDAS) score.
Inclusion: Children of any gender; Aged 8-15 years; Diagnosed with migraine (with/without aura) per International Classification of Headache Disorders, 3rd Edition (ICHD-3) criteria; A history of ≥4 migraine attacks/month for the preceding 3 months; With a PedMIDAS score ≥11 (moderate-to-severe impact).
Exclusion: Children with secondary headache disorders (e.g., due to infections, trauma, structural brain lesions); Known hypersensitivity or contraindications to flunarizine or propranolol; Presence of cardiovascular disorders (e.g., bradycardia, heart block, hypotension, asthma); Non-compliance or inability to attend regular follow-ups; Participation in another clinical trial within the last 3 months.